Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 14/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148234 | 0.91 | MALT1 (0.35) | MALT1 | |
| SCHEMBL1148400 | 0.90 | MALT1 (0.37) | MALT1DRD4 | |
| SCHEMBL1148148 | 0.90 | MALT1 (0.38) | MALT1DRD4TP53MAPTPPARD | |
| SCHEMBL1148604 | 0.90 | MALT1 (0.37) | MALT1DRD4 | |
| SCHEMBL1148149 | 0.88 | MALT1 (0.37) | MALT1 | |
| SCHEMBL1148390 | 0.87 | MALT1 (0.36) | MALT1TP53MAPT | |
| SCHEMBL1148159 | 0.87 | MALT1 (0.37) | MALT1DRD4TP53MAPTPPARD | |
| SCHEMBL1148275 | 0.86 | MALT1 (0.36) | MALT1TP53MAPT | |
| SCHEMBL13242829 | 0.85 | MALT1 (0.42) | MALT1DRD4MAPTPPARD | |
| SCHEMBL13356325 | 0.85 | MALT1 (0.44) | MALT1DRD4GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | MALT1 3967/4885DRD4 3861/4885TP53 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.